Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China
· Delayed Price · Currency is CNY 7.08
+0.02 (0.28%)
Mar 10, 2026, 2:14 PM CST
SHA:600223 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 7,177 | 7,685 | 9,790 | 10,765 | 13,371 | 8,595 | Upgrade
|
| Market Cap Growth | -1.67% | -21.50% | -9.06% | -19.49% | 55.57% | 1.86% | Upgrade
|
| Enterprise Value | 5,328 | 5,881 | 12,411 | 15,213 | 21,219 | 16,887 | Upgrade
|
| Last Close Price | 7.06 | 7.51 | 9.34 | 10.27 | 12.69 | 8.06 | Upgrade
|
| PE Ratio | 33.60 | 31.56 | 32.27 | 236.84 | 36.95 | 13.46 | Upgrade
|
| Forward PE | 26.15 | 33.64 | 33.64 | 33.64 | 33.64 | 33.64 | Upgrade
|
| PS Ratio | 1.90 | 1.93 | 2.14 | 0.83 | 1.08 | 0.63 | Upgrade
|
| PB Ratio | 1.47 | 1.61 | 2.09 | 1.93 | 2.06 | 1.32 | Upgrade
|
| P/TBV Ratio | 1.85 | 2.03 | 2.64 | 3.20 | 3.07 | 2.32 | Upgrade
|
| P/FCF Ratio | 91.24 | 107.58 | 37.25 | 12.94 | 2.04 | 2.00 | Upgrade
|
| P/OCF Ratio | 34.85 | 33.61 | 20.65 | 10.79 | 1.95 | 1.93 | Upgrade
|
| EV/Sales Ratio | 1.41 | 1.48 | 2.71 | 1.18 | 1.72 | 1.24 | Upgrade
|
| EV/EBITDA Ratio | 23.78 | 19.07 | 34.14 | 21.98 | 29.09 | 19.82 | Upgrade
|
| EV/EBIT Ratio | 34.12 | 27.39 | 54.51 | 26.43 | 33.32 | 22.05 | Upgrade
|
| EV/FCF Ratio | 67.74 | 82.33 | 47.23 | 18.29 | 3.23 | 3.94 | Upgrade
|
| Debt / Equity Ratio | 0.04 | 0.06 | 0.47 | 1.39 | 1.43 | 1.76 | Upgrade
|
| Debt / EBITDA Ratio | 0.89 | 0.91 | 5.81 | 11.09 | 12.71 | 13.46 | Upgrade
|
| Debt / FCF Ratio | 2.54 | 4.00 | 8.30 | 9.30 | 1.41 | 2.67 | Upgrade
|
| Net Debt / Equity Ratio | -0.52 | -0.56 | 0.10 | 0.61 | 0.64 | 0.98 | Upgrade
|
| Net Debt / EBITDA Ratio | -11.69 | -8.63 | 1.23 | 4.94 | 5.69 | 7.51 | Upgrade
|
| Net Debt / FCF Ratio | -32.43 | -37.26 | 1.71 | 4.11 | 0.63 | 1.49 | Upgrade
|
| Asset Turnover | 0.63 | 0.58 | 0.14 | 0.22 | 0.20 | 0.23 | Upgrade
|
| Inventory Turnover | 3.31 | 3.49 | 0.11 | 0.21 | 0.20 | 0.24 | Upgrade
|
| Quick Ratio | 3.78 | 3.15 | 2.24 | 0.12 | 0.13 | 0.12 | Upgrade
|
| Current Ratio | 4.51 | 3.75 | 2.49 | 1.10 | 1.15 | 1.17 | Upgrade
|
| Return on Equity (ROE) | 5.50% | 6.26% | 7.15% | 1.08% | 6.05% | 11.39% | Upgrade
|
| Return on Assets (ROA) | 1.64% | 1.94% | 0.43% | 0.60% | 0.65% | 0.81% | Upgrade
|
| Return on Invested Capital (ROIC) | 6.02% | 5.07% | 2.86% | 1.46% | 3.31% | 4.68% | Upgrade
|
| Return on Capital Employed (ROCE) | 3.20% | 4.40% | 4.20% | 7.30% | 6.20% | 7.00% | Upgrade
|
| Earnings Yield | 2.98% | 3.17% | 3.10% | 0.42% | 2.71% | 7.43% | Upgrade
|
| FCF Yield | 1.10% | 0.93% | 2.68% | 7.73% | 49.11% | 49.92% | Upgrade
|
| Dividend Yield | 1.69% | 1.47% | 1.07% | 1.07% | 0.87% | 2.48% | Upgrade
|
| Payout Ratio | 55.39% | 75.38% | 160.84% | 2585.08% | 556.88% | 354.89% | Upgrade
|
| Buyback Yield / Dilution | -2.90% | -0.34% | 11.01% | -9.90% | -2.00% | -0.05% | Upgrade
|
| Total Shareholder Return | -1.21% | 1.13% | 12.08% | -8.83% | -1.13% | 2.43% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.